See more : Fraport AG (FPRUF) Income Statement Analysis – Financial Results
Complete financial analysis of Bicycle Therapeutics plc (BCYC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bicycle Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- China Information Technology Development Limited (8178.HK) Income Statement Analysis – Financial Results
- CHTC Fong’s International Company Limited (0641.HK) Income Statement Analysis – Financial Results
- HeartBeam, Inc. (BEAT) Income Statement Analysis – Financial Results
- JASON (4570.TWO) Income Statement Analysis – Financial Results
- OrthoPediatrics Corp. (KIDS) Income Statement Analysis – Financial Results
Bicycle Therapeutics plc (BCYC)
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.98M | 14.46M | 11.70M | 10.39M | 13.80M | 7.14M | 2.06M | 0.00 |
| Cost of Revenue | 6.47M | 3.69M | 44.88M | 33.15M | 25.54M | 20.76M | 11.87M | 269.29K |
| Gross Profit | 20.51M | 10.78M | -33.18M | -22.76M | -11.74M | -13.63M | -9.81M | -269.29K |
| Gross Profit Ratio | 76.03% | 74.51% | -283.69% | -219.05% | -85.06% | -190.93% | -476.02% | 0.00% |
| Research & Development | 156.50M | 81.61M | 44.88M | 33.15M | 25.54M | 20.76M | 11.87M | 9.77M |
| General & Administrative | 59.83M | 49.51M | 32.44M | 29.20M | 14.56M | 8.12M | 6.41M | 3.78M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -325.11K |
| SG&A | 59.83M | 49.51M | 32.44M | 29.20M | 14.56M | 8.12M | 6.41M | 3.45M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -5.38M | -665.00K | -119.00K | 0.00 |
| Operating Expenses | 216.92M | 131.12M | 77.32M | 62.35M | 40.10M | 28.88M | 18.27M | 13.22M |
| Cost & Expenses | 216.92M | 131.12M | 77.32M | 62.35M | 40.10M | 28.88M | 18.27M | 13.49M |
| Interest Income | 14.00M | 5.76M | 120.00K | 683.00K | 814.00K | 169.00K | 50.00K | 8.00K |
| Interest Expense | 3.26M | 3.34M | 2.98M | 457.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.55M | 3.69M | 1.41M | 1.29M | 963.97K | 710.80K | 335.56K | 269.29K |
| EBITDA | -183.40M | -112.96M | -64.08M | -50.39M | -30.03M | -21.49M | -15.88M | -13.26M |
| EBITDA Ratio | -679.86% | -766.76% | -559.96% | -493.52% | -190.56% | -294.76% | -770.92% | 0.00% |
| Operating Income | -189.95M | -116.65M | -65.62M | -51.96M | -26.30M | -21.75M | -16.21M | -13.49M |
| Operating Income Ratio | -704.13% | -806.56% | -560.98% | -500.10% | -190.56% | -304.74% | -787.04% | 0.00% |
| Total Other Income/Expenses | 10.74M | 2.41M | -2.86M | 226.00K | -4.56M | -496.00K | -69.00K | -37.90K |
| Income Before Tax | -179.21M | -114.24M | -68.48M | -51.73M | -30.86M | -22.24M | -16.28M | -13.53M |
| Income Before Tax Ratio | -664.32% | -789.88% | -585.47% | -497.92% | -223.62% | -311.69% | -790.39% | 0.00% |
| Income Tax Expense | 1.46M | -1.52M | -1.66M | -724.00K | -254.00K | -396.00K | -23.00K | -20.94K |
| Net Income | -180.66M | -112.72M | -66.82M | -51.01M | -30.61M | -21.85M | -16.26M | -13.51M |
| Net Income Ratio | -669.72% | -779.35% | -571.25% | -490.95% | -221.78% | -306.14% | -789.27% | 0.00% |
| EPS | -5.08 | -3.80 | -2.67 | -2.66 | -2.77 | -1.64 | -1.22 | -0.76 |
| EPS Diluted | -5.08 | -3.80 | -2.67 | -2.66 | -2.77 | -1.64 | -1.22 | -0.76 |
| Weighted Avg Shares Out | 35.59M | 29.66M | 25.06M | 19.15M | 11.05M | 13.29M | 13.29M | 17.70M |
| Weighted Avg Shares Out (Dil) | 35.59M | 29.66M | 25.06M | 19.15M | 11.05M | 13.29M | 13.29M | 17.70M |
Bicycle Therapeutics: Platform Technology Has Potential; Move To Combination Therapy With Opdivo Is Next
BCYC Stock: Why The Price Substantially Increased This Past Week
Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares
BCYC Stock: Why It Substantially Increased Today
Bicycle Therapeutics Stock Falls After Interim Data Of Toxin Conjugates In Ovarian Cancer Trial
Bicycle Therapeutics to Present BT5528 Interim Phase I Data at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
3 Biotech Stocks That Soared to New Heights Last Week
Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs
Bicycle, Ionis To Develop Targeted Oligonucleotide Therapeutics
Source: https://incomestatements.info
Category: Stock Reports